А. А. Божок

2.7k total citations · 1 hit paper
22 papers, 2.0k citations indexed

About

А. А. Божок is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, А. А. Божок has authored 22 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cancer Research, 12 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in А. А. Божок's work include Breast Cancer Treatment Studies (16 papers), Cancer Treatment and Pharmacology (9 papers) and Advanced Breast Cancer Therapies (6 papers). А. А. Божок is often cited by papers focused on Breast Cancer Treatment Studies (16 papers), Cancer Treatment and Pharmacology (9 papers) and Advanced Breast Cancer Therapies (6 papers). А. А. Божок collaborates with scholars based in Russia, Spain and Italy. А. А. Божок's co-authors include Semiglazov Vf, Luca Gianni, Pinuccia Valagussa, Milvia Zambetti, Aňa Lluch, W. Eiermann, José Baselga, Eva Ciruelos, Mikhail Lichinitser and B. Ojeda and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

А. А. Божок

19 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

2010 891 citations Luca Gianni, W. Eiermann et al. The Lancet profile →

Peers

Countries citing papers authored by А. А. Божок

Since Specialization

Citations

This map shows the geographic impact of А. А. Божок's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by А. А. Божок with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites А. А. Божок more than expected).

Fields of papers citing papers by А. А. Божок

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by А. А. Божок. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by А. А. Божок. The network helps show where А. А. Божок may publish in the future.

Co-authorship network of co-authors of А. А. Божок

This figure shows the co-authorship network connecting the top 25 collaborators of А. А. Божок. A scholar is included among the top collaborators of А. А. Божок based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with А. А. Божок. А. А. Божок is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Circumlateral vertical mastopexy in tuberous breast deformity 2022 ·(unknown), (unknown), А. А. Божок, (unknown)	1
2	Questions of axillary region surgery in breast cancer patients after systemic neoadjuvant therapy 2021 ·SHILAP Revista de lepidopterología ·А. А. Божок, (unknown), (unknown), (unknown)	0
3	Clinical and morphological characteristics of skin and subcutaneous fat damage after surgical treatment and radiation therapy in patients with breast cancer (literature review) 2017 ·Tumors of female reproductive system ·Э. Э. Топузов, (unknown), А. А. Божок, G. A. Dashyan, (unknown), (unknown), (unknown)	3
4	Evaluation of the scientific results of the study entitled “Opportunities for surgical treatment of patients with stage IV breast cancer” performed by Russian Society of Oncomammologists (RSOM) 2016 ·Tumors of female reproductive system ·А. А. Божок, Э. Э. Топузов, (unknown), (unknown), (unknown), (unknown), (unknown), Р. М. Палтуев	3
5	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort 2014 ·The Lancet Oncology ·Luca Gianni, W. Eiermann, Semiglazov Vf, Aňa Lluch, Sergei Tjulandin, Milvia Zambetti, Angela Moliterni, Federico Vázquez, M. Byakhov, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Domenico Magazzù, Dominik Heinzmann, Jutta Steinseifer, Pinuccia Valagussa, José Baselga	356
6	Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. 2013 ·Journal of Clinical Oncology ·Luca Gianni, W. Eiermann, Semiglazov Vf, Alexey Manikhas, Aňa Lluch, Sergei Tjulandin, Milvia Zambetti, Federico Vázquez, M. Byakhov, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Domenico Magazzù, Jutta Steinseifer, Pinuccia Valagussa, José Baselga	11
7	Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study 2011 ·European Journal of Surgical Oncology ·Semiglazov Vf, W. Eiermann, Milvia Zambetti, Alexey Manikhas, А. А. Божок, Aňa Lluch, S. Tjulandin, (unknown), A Caballero, Pinuccia Valagussa, José Baselga, Luca Gianni	40
8	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort breakdown → 2010 ·The Lancet ·Luca Gianni, W. Eiermann, Semiglazov Vf, Alexey Manikhas, Aňa Lluch, S. Tjulandin, Milvia Zambetti, Federico Vázquez, Mikhail Byakhow, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Roberta Baronio, A. Feyereislova, Claire Barton, Pinuccia Valagussa, José Baselga	891
9	Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer 2009 ·Journal of Clinical Oncology ·Luca Gianni, José Baselga, W. Eiermann, (unknown), Semiglazov Vf, Aňa Lluch, Milvia Zambetti, (unknown), Günther Raab, Antonio Llombart‐Cussac, А. А. Божок, Ángel Martínez-Agulló, Marco Greco, Mikhail Byakhov, Juan José López Gómez, Mauro Mansutti, Pinuccia Valagussa, Gianni Bonadonna	157
10	0177 Primary endocrine therapy versus chemotherapy in postmenopausal patients with ER-positive breast cancer: 5-year results 2009 ·The Breast ·Semiglazov Vf, G. A. Dashyan, В. В. Семиглазов, E.K. Ziltsova, (unknown), В Г Иванов, (unknown), А. А. Божок, Р. М. Палтуев, Lev M. Berstein	0
11	Prognostic and predictive factors in breast cancer 2008 ·PubMed ·А. А. Божок, В. В. Семиглазов, (unknown), (unknown)	11
12	Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer 2007 ·Cancer ·Semiglazov Vf, В. В. Семиглазов, G. A. Dashyan, E.K. Ziltsova, В Г Иванов, А. А. Божок, Ольга Александровна Мельникова, Р. М. Палтуев, (unknown), Lev M. Berstein	224
13	[Inflammatory breast carcinoma and prognosticators of efficacy of primary chemotherapy]. 2007 ·PubMed ·Semiglazov Vf, (unknown), А. А. Божок, (unknown), (unknown), (unknown), (unknown), Р. М. Палтуев, (unknown), (unknown), (unknown), (unknown), (unknown)	1
14	[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer]. 2007 ·PubMed ·В. В. Семиглазов, (unknown), (unknown), В Г Иванов, А. А. Божок, (unknown), Р. М. Палтуев, Ольга Александровна Мельникова, (unknown), Petr Krivorotko, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
15	Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy 2005 ·Clinical Cancer Research ·Luca Gianni, José Baselga, W. Eiermann, V. Guillem Porta, Semiglazov Vf, Aňa Lluch, Milvia Zambetti, (unknown), Günther Raab, Antonio Llombart‐Cussac, А. А. Божок, Ángel Martínez-Agulló, Marco Greco, Mikhail Byakhov, Juan José López Gómez, Mauro Mansutti, Pinuccia Valagussa, Gianni Bonadonna, (unknown)	126
16	P85 Direct comparison of primary (neoadjuvant) endocrine therapy vs primary chemotherapy in postmenopausal women with ER-positive breast cancer 2005 ·The Breast ·Semiglazov Vf, (unknown), А. А. Божок, (unknown), (unknown), (unknown), Р. М. Палтуев, G. A. Dashyan, Lev M. Berstein, (unknown)	2
17	The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer 2004 ·Journal of Clinical Oncology ·Semiglazov Vf, Vladimir Semiglazov, В Г Иванов, А. А. Божок, E.K. Ziltsova, Р. М. Палтуев, (unknown), (unknown), Э. Э. Топузов, Lev M. Berstein	16
18	The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer 2004 ·Journal of Clinical Oncology ·Semiglazov Vf, В Г Иванов, А. А. Божок, E.K. Ziltsova, Р. М. Палтуев, (unknown), (unknown), Э. Э. Топузов, Lev M. Berstein	44
19	Preoperative hormonal therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients 2004 ·European Journal of Cancer Supplements ·Semiglazov Vf, В. В. Семиглазов, (unknown), E.K. Ziltsova, (unknown), (unknown), А. А. Божок, Э. Э. Топузов, Р. М. Палтуев, Lev M. Berstein	3
20	Anastrazol (A) vs tamoxifen (T) vs combine (A+T) as neoadjuvant endocrine therapy of postmenopausal breast cancer patients 2003 ·The Breast ·Semiglazov Vf, В. В. Семиглазов, В Г Иванов, (unknown), G. A. Dashyan, (unknown), А. А. Божок, (unknown), (unknown), Lev M. Berstein	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact